VELA Investment Management LLC Has $2.26 Million Stock Position in Indivior PLC (NASDAQ:INDV)

VELA Investment Management LLC raised its stake in Indivior PLC (NASDAQ:INDVFree Report) by 45.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 179,659 shares of the company’s stock after buying an additional 56,224 shares during the period. VELA Investment Management LLC’s holdings in Indivior were worth $2,264,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior in the fourth quarter valued at approximately $56,000. Stifel Financial Corp acquired a new position in shares of Indivior during the third quarter worth $100,000. Melqart Asset Management UK Ltd acquired a new position in shares of Indivior during the third quarter worth $132,000. Jane Street Group LLC acquired a new position in shares of Indivior during the third quarter worth $180,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Indivior during the third quarter worth $294,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Up 3.5 %

Shares of NASDAQ INDV opened at $8.88 on Friday. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $23.22. The firm has a fifty day simple moving average of $11.19 and a 200 day simple moving average of $10.71. The company has a market capitalization of $1.22 billion, a PE ratio of -25.37 and a beta of 0.73.

Indivior (NASDAQ:INDVGet Free Report) last announced its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. As a group, equities analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the topic of a number of recent research reports. Rodman & Renshaw initiated coverage on shares of Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

Check Out Our Latest Stock Analysis on Indivior

About Indivior

(Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Recommended Stories

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDVFree Report).

Institutional Ownership by Quarter for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.